Study identifier:1839IL/0525
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Conventional Postoperative Radiotherapy (Standard Fractionation) Plus Iressa or Hyperfractionated Radiotherapy plus Cisplatin and Iressa for Advanced Head & Neck Cancer: A Phase I Pilot Trial
head and neck cancer
Phase 1
No
Gefitinib
All
30
Interventional
18 Years +
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 post operative combination of gefinib and RT | Drug: Gefitinib 250 mg; oral Other Name: IRESSA (TM) |
Experimental: Cohort 2 combination of gefitinib with RT and Chemotherapy in non operated patients | Drug: Gefitinib 250mg; oral Other Name: IRESSA (TM) |